Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Alder BioPharma's Eptinezumab Meets Primary Endpoint | Contract Pharma

What are you searching for?

Sign in
Breaking News

Alder BioPharma’s Eptinezumab Meets Primary Endpoint

In its pivotal Phase 3 PROMISE 2 clinical trial

By: Betsy Louda

, Contract Pharma

Alder BioPharmaceuticals announced that eptinezumab, its lead investigational product candidate for migraine prevention targeting calcitonin gene-related peptide (CGRP), met the primary endpoint in its pivotal Phase 3 PROMISE 2 clinical trial with very high statistical significance for both dose levels tested in the trial following a single quarterly infusion. 

 

In addition, eptinezumab met all key secondary endpoints with very high statistical significance vs. placebo including prevention. Furthermore, 15% of eptinezumab patients had no migraines for a full three months. 

 

“These clinically significant data clearly demonstrate that eptinezumab delivered by infusion provided rapid, effective and sustained migraine relief,” said Randall C. Schatzman, Ph.D., president and chief executive officer of Alder. “With these PROMISE 2 results, we remain on track to submit our Biologics License Application (BLA) in the second half of 2018. 

 

More than 2,600 patients have been treated with eptinezumab in its clinical development program, including the PROMISE 1 and PROMISE 2 trials.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics